US's FluMist can now be administered by a healthcare provider or by recipient or caregiver aged 18 or above. India's Nasovac S4 faces hurdles like cost, availability & low acceptance.
MenFive targets 5 causes of meningococcal meningitis, a bacterial infection that can kill within hours. It can cause severe brain damage and sepsis, and is fatal in 50% cases if untreated.
Pune-based SII has got the go-ahead from the Drugs Controller General of India to market the vaccine. Cervical cancer is one of the leading causes of female cancer mortality worldwide.
Cervical cancer in India is the 2nd most frequent cancer among women between 15-44 years of age. Currently, India is fully dependent on foreign manufacturers for the vaccine.
SII's Director of Government and Regulatory Affairs is learnt to have recently communicated to Union Health Ministry that it has a manufactured stock of 24,89,15,000 Covishield doses.
Serum Institute of India, world's largest vaccine manufacturer, will market the nanoparticle protein-based vaccine in Indonesia under the brand name Covovax.
DMK govt accuses Centre of withholding funds, tightening borrowing, unilateral deductions from state accounts. Says Centre's accounting & funding decisions have 'artificially inflated' debt burden.
This is the game every nation is now learning to play. Some are finding new allies or seeing value among nations where they’d seen marginal interest. The starkest example is India & Europe.
COMMENTS